Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,835Open textbooks209Open-access articles1,406Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology182Genetics and Genomics170Neuroscience185Cardiovascular Medicine180Immunology142Pharmacology173Molecular Biology161Infectious Diseases150Rare and Inherited Diseases181Clinical Research173Anatomy and Physiology613Drugs and Chemicals621Psychiatry and Psychology185Public Health and Nutrition178Diagnostics and Medical Technology125Respiratory Medicine113Digestive System and Liver91Metabolism and Endocrine Disease177Bones, Joints, Muscles and Skin213Kidney, Urology and Women's Health173Eye, Ear, Nose and Throat55
Plans & pricingCompare EvidenceHelix workspace plans
Library›Open textbooks›An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT›References

Continue where you left off ()

Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT · References

References

CC BY 4.0 · NIHR Journals Library · approximately 13 min read

  1. UK Cystic Fibrosis Registry. UK Cystic Fibrosis Registry Annual Data Report 2018. London: Cystic Fibrosis Trust; 2019.
  2. Davies JC, Alton EWFW, Bush A. Cystic fibrosis. BMJ 2007;335:1255. 10.1136/bmj.39391.713229.AD18079549
  3. Villanueva G, Marceniuk G, Murphy MS, Walshaw M, Cosulich R, Guideline Committee. Diagnosis and management of cystic fibrosis: summary of NICE guidance. BMJ 2017;359:j4574. 10.1136/bmj.j457429074599
  4. Quon BS, Rowe SM. New and emerging targeted therapies for cystic fibrosis. BMJ 2016;352:i859. 10.1136/bmj.i85927030675
  5. O’Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009;373:1891–904. 10.1016/S0140-6736(09)60327-519403164
  6. Southern KW, Barker PM, Solis-Moya A, Patel L, Cochrane Cystic Fibrosis and Genetic Disorders Group. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2012;11:CD002203. 10.1002/14651858.CD002203.pub4
  7. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365:1663–72. 10.1056/NEJMoa110518522047557
  8. McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008;178:921–8. 10.1164/rccm.200712-1804OC18658109
  9. Ryan G, Mukhopadhyay S, Singh M. Nebulised anti-pseudomonal antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2003;3:CD001021. 10.1002/14651858.CD001021
  10. Jones AP, Wallis C. Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev 2010;3:CD001127. 10.1002/14651858.CD001127.pub2
  11. Wark P, McDonald VM. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev 2009;2:CD001506. 10.1002/14651858.CD001506.pub3
  12. Ryan G, Singh M, Dwan K. Inhaled antibiotics for long-term therapy in cystic fibrosis. Cochrane Database Syst Rev 2011;3:CD001021. 10.1002/14651858.CD001021.pub2
  13. Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros 2009;8:91–6. 10.1016/j.jcf.2008.09.00718952504
  14. Sawicki GS, Tiddens H. Managing treatment complexity in cystic fibrosis: challenges and opportunities. Pediatr Pulmonol 2012;47:523–33. 10.1002/ppul.2254622467341
  15. World Health Organization (WHO). Adherence to Long-Term Therapies: Evidence for Action. Geneva: WHO; 2003.
  16. Daniels T, Goodacre L, Sutton C, Pollard K, Conway S, Peckham D. Accurate assessment of adherence: self-report and clinician report vs electronic monitoring of nebulizers. Chest 2011;140:425–32. 10.1378/chest.09-307421330381
  17. McNamara PS, McCormack P, McDonald AJ, Heaf L, Southern KW. Open adherence monitoring using routine data download from an adaptive aerosol delivery nebuliser in children with cystic fibrosis. J Cyst Fibros 2009;8:258–63. 10.1016/j.jcf.2009.04.00619447080
  18. Eakin MN, Bilderback A, Boyle MP, Mogayzel PJ, Riekert KA. Longitudinal association between medication adherence and lung health in people with cystic fibrosis. J Cyst Fibros 2011;10:258–64. 10.1016/j.jcf.2011.03.00521458391
  19. Briesacher BA, Quittner AL, Saiman L, Sacco P, Fouayzi H, Quittell LM. Adherence with tobramycin inhaled solution and health care utilization. BMC Pulm Med 2011;11:5. 10.1186/1471-2466-11-521251275
  20. Smyth A, Lewis S, Bertenshaw C, Choonara I, McGaw J, Watson A. Case-control study of acute renal failure in patients with cystic fibrosis in the UK. Thorax 2008;63:532–5. 10.1136/thx.2007.08875718245146
  21. Mayer-Hamblett N, Rosenfeld M, Emerson J, Goss CH, Aitken ML. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med 2002;166:1550–5. 10.1164/rccm.200202-087OC12406843
  22. de Boer K, Vandemheen KL, Tullis E, Doucette S, Fergusson D, Freitag A, et al. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax 2011;66:680–5. 10.1136/thx.2011.16111721680566
  23. Quittner AL, Zhang J, Marynchenko M, Chopra PA, Signorovitch J, Yushkina Y, Riekert KA. Pulmonary medication adherence and health-care use in cystic fibrosis. Chest 2014;146:142–51. 10.1378/chest.13-192624480974
  24. Tappenden P, Sadler S, Wildman M. An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis. PharmacoEconomics 2017;35:647–59. 10.1007/s40273-017-0500-x28337719
  25. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M, Medical Research Council Guidance. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ 2008;337:a1655. 10.1136/bmj.a165518824488
  26. Horne RW, Barber N, Elliot R, Morgan M. Concordance, Adherence and Compliance in Medicine Taking. Report for the National Co-ordinating Centre for NHS Service Delivery and Organisational R&D (NCCSDO). London: NCCSDO; 2005.
  27. James Lind Alliance. Cystic Fibrosis Top 10. URL: www.jla.nihr.ac.uk/priority-setting-partnerships/cystic-fibrosis/top-10-priorities.htm
  28. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994;331:637–42. 10.1056/NEJM1994090833110037503821
  29. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354:229–40. 10.1056/NEJMoa04390016421364
  30. Shippee ND, Domecq Garces JP, Prutsky Lopez GJ, Wang Z, Elraiyah TA, Nabhan M, et al. Patient and service user engagement in research: a systematic review and synthesized framework. Health Expect 2015;18:1151–66. 10.1111/hex.1209023731468
  31. Ritchie J, Spencer L. Qualitative Data Analysis for Applied Policy Research. In Bryman A, Burgess RG, editors. Analysing Qualitative Data. London: Routledge; 1994 pp. 173–94. 10.4324/9780203413081_chapter_9
  32. Cane J, O’Connor D, Michie S. Validation of the theoretical domains framework for use in behaviour change and implementation research. Implement Sci 2012;7:37. 10.1186/1748-5908-7-3722530986
  33. Drabble SJ, O’Cathain A, Arden MA, Hutchings M, Beever D, Wildman M. When Is forgetting not forgetting? a discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. Qual Health Res 2019;29:2119–31. 10.1177/104973231985658031303116
  34. Arden MA, Drabble S, O’Cathain A, Hutchings M, Wildman M. Adherence to medication in adults with Cystic Fibrosis: an investigation using objective adherence data and the Theoretical Domains Framework. Br J Health Psychol 2019;24:357–80. 10.1111/bjhp.1235730825258
  35. O’Cathain A, Croot L, Sworn K, Duncan E, Rousseau N, Turner K, et al. Taxonomy of approaches to developing interventions to improve health: a systematic methods overview. Pilot Feasibility Stud 2019;5:41. 10.1186/s40814-019-0425-630923626
  36. O’Cathain A, Croot L, Duncan E, Rousseau N, Sworn K, Turner KM, et al. Guidance on how to develop complex interventions to improve health and healthcare. BMJ Open 2019;9:e029954. 10.1136/bmjopen-2019-029954
  37. Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci 2011;6:42. 10.1186/1748-5908-6-4221513547
  38. Yardley L, Morrison L, Bradbury K, Muller I. The person-based approach to intervention development: application to digital health-related behavior change interventions. J Med Internet Res 2015;17:e30. 10.2196/jmir.405525639757
  39. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ 2014;348:g1687. 10.1136/bmj.g168724609605
  40. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 1999;14:1–24. 10.1080/08870449908407311
  41. Hind D, Drabble SJ, Arden MA, Mandefield L, Waterhouse S, Maguire C, et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study. BMC Pulm Med 2019;19:77. 10.1186/s12890-019-0834-630975206
  42. Drabble SJ, O’Cathain A, Scott AJ, Arden MA, Keating S, Hutchings M, et al. Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study. J Med Internet Res 2020;22:e16782. 10.2196/1678232697197
  43. Hind D, Drabble SJ, Arden MA, Mandefield L, Waterhouse S, Maguire C, et al. Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open 2020;10:e039089. 10.1136/bmjopen-2020-039089
  44. Wildman MJ, O’Cathain A, Maguire C, Arden MA, Hutchings M, Bradley J, et al. Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial [published online ahead of print September 23 2021]. Thorax 2021. 10.1136/thoraxjnl-2021-217594
  45. Moore GF, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, et al. Process evaluation of complex interventions: Medical Research Council guidance. BMJ 2015;350:h1258. 10.1136/bmj.h125825791983
  46. Wildman M, Hutchings M, Arden M, O’Cathain A, Drabble S, Walters SJ, et al. Development and Evaluation of an Intervention to Support Adherence to Treatment in Adults with Cystic Fibrosis: A Randomised Controlled Trial and Parallel Process Evaluation Protocol. Sheffield: Sheffield Teaching Hospitals NHS Foundation Trust; 2018. URL: https://figshare.shef.ac.uk/articles/journal_contribution/Development_and_evaluation_of_an_intervention_to_support_Adherence_to_treatment_in_adults_with_Cystic_Fibrosis_A_randomised_controlled_trial_and_parallel_process_evaluation_protocol/7338815 (accessed June 2021).
  47. Ratjen F, Durham T, Navratil T, Schaberg A, Accurso FJ, Wainwright C, et al. Long term effects of denufosol tetrasodium in patients with cystic fibrosis. J Cyst Fibros 2012;11:539–49. 10.1016/j.jcf.2012.05.00322682898
  48. Altman D, Machin D, Bryant T, Gardner M (editors). Statistics with Confidence: Confidence Intervals and Statistical Guidelines, 2nd edition. London: BMJ Books; 2000.
  49. Altman DG, Machin D, Bryant TN, Gardner MJ. Statistics with confidence. 2nd edn. London: BMJ; 2000.
  50. Perneger TV. What’s wrong with Bonferroni adjustments. BMJ 1998;316:1236–8. 10.1136/bmj.316.7139.12369553006
  51. Farmer T, Robinson K, Elliott SJ, Eyles J. Developing and implementing a triangulation protocol for qualitative health research. Qual Health Res 2006;16:377–94. 10.1177/104973230528570816449687
  52. O’Cathain A. A Practical Guide to Using Qualitative Research with Randomized Controlled Trials. Oxford: Oxford University Press; 2018. 10.1093/med/9780198802082.001.0001
  53. Oakley A, Strange V, Bonell C, Allen E, Stephenson J, RIPPLE Study Team. Process evaluation in randomised controlled trials of complex interventions. BMJ 2006;332:413–16. 10.1136/bmj.332.7538.41316484270
  54. Borrelli B. The assessment, monitoring, and enhancement of treatment fidelity in public health clinical trials. J Public Health Dent 2011;71(Suppl. 1):52–63. 10.1111/j.1752-7325.2011.00233.x
  55. Vassilev I, Rowsell A, Pope C, Kennedy A, O’Cathain A, Salisbury C, Rogers A. Assessing the implementability of telehealth interventions for self-management support: a realist review. Implement Sci 2015;10:59. 10.1186/s13012-015-0238-925906822
  56. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ 2013;346:f1049. 10.1136/bmj.f104923529982
  57. van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 2012;15:708–15. 10.1016/j.jval.2012.02.00822867780
  58. NHS Improvement. NHS Reference Costs 2017/18. London: NHS Improvement; 2018.
  59. Curtis LA, Burns A. Unit Costs of Health and Social Care 2018. Canterbury: Personal Social Services Research Unit; 2018.
  60. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med 2011;30:377–99. 10.1002/sim.406721225900
  61. Willan AR, Lin DY, Manca A. Regression methods for cost-effectiveness analysis with censored data. Stat Med 2005;24:131–45. 10.1002/sim.179415515137
  62. Tappenden P, Harnan S, Uttley L, Mildred M, Carroll C, Cantrell A. Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: systematic review and economic model. Health Technol Assess 2013;17(56). 10.3310/hta17560
  63. Office for National Statistics (ONS). National Life Tables: England. London: ONS; 2019.
  64. Keogh RH, Szczesniak R, Taylor-Robinson D, Bilton D. Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry data. J Cyst Fibros 2018;17:218–27. 10.1016/j.jcf.2017.11.01929311001
  65. Cystic Fibrosis Trust. CF Registry Bespoke Dataset (Years 2006–2015; Data Held on File). URL: www.cysticfibrosis.org.uk/the-work-we-do/uk-cf-registry/reporting-and-resources (accessed 20 July 2021).
  66. Anyanwu AC, McGuire A, Rogers CA, Murday AJ. Assessment of quality of life in lung transplantation using a simple generic tool. Thorax 2001;56:218–22. 10.1136/thorax.56.3.21811182015
  67. Hernández Alava M, Wailoo A. Fitting adjusted limited dependent variable mixture models to EQ-5D. Stata J 2015;15:737–50. 10.1177/1536867X1501500307
  68. Hernández Alava M, Wailoo AJ, Ara R. Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values. Value Health 2012;15:550–61. 10.1016/j.jval.2011.12.01422583466
  69. Hernández Alava M, Wailoo A, Pudney S, Gray L, Manca A. Modelling generic preference-based outcome measures: development and comparison of methods. Health Technol Assess 2019;24(34). 10.3310/hta24340
  70. Wailoo AJ, Hernandez-Alava M, Manca A, Mejia A, Ray J, Crawford B, et al. Mapping to estimate health-state utility from non-preference-based outcome measures: an ISPOR Good Practices for Outcomes Research Task Force Report. Value Health 2017;20:18–27. 10.1016/j.jval.2016.11.00628212961
  71. Ara R, Brazier JE. Populating an economic model with health state utility values: moving toward better practice. Value Health 2010;13:509–18. 10.1111/j.1524-4733.2010.00700.x20230546
  72. Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharamceutical Press. URL: www.medicinescomplete.com (12 May 2021).
  73. Quittner AL, Eakin MN, Alpern AN, Ridge AK, McLean KA, Bilderback A, et al. Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis. J Cyst Fibros 2019;18:879–85. 10.1016/j.jcf.2019.05.00431103533
  74. Sagel SD, Khan U, Jain R, Graff G, Daines CL, Dunitz JM, et al. Effects of an antioxidant-enriched multivitamin in cystic fibrosis. A randomized, controlled, multicenter clinical trial. Am J Respir Crit Care Med 2018;198:639–47. 10.1164/rccm.201801-0105OC29688760
  75. Bruzzese E, Raia V, Ruberto E, Scotto R, Giannattasio A, Bruzzese D, et al. Lack of efficacy of Lactobacillus GG in reducing pulmonary exacerbations and hospital admissions in children with cystic fibrosis: a randomised placebo controlled trial. J Cyst Fibros 2018;17:375–82. 10.1016/j.jcf.2017.10.01429128317
  76. Goldbeck L, Fidika A, Herle M, Quittner AL. Psychological interventions for individuals with cystic fibrosis and their families. Cochrane Database Syst Rev 2014;6:CD003148. 10.1002/14651858.CD003148.pub3
  77. Savage E, Beirne PV, Ni Chroinin M, Duff A, Fitzgerald T, Farrell D. Self-management education for cystic fibrosis. Cochrane Database Syst Rev 2014;9:CD007641. 10.1002/14651858.CD007641.pub3
  78. Palmer R, Harrison M, Cross E, Enderby P. Negotiating excess treatment costs in a clinical research trial: the good, the bad and the innovative. Trials 2016;17:71. 10.1186/s13063-016-1208-526860107
  79. Vandevanter DR, Yegin A, Morgan WJ, Millar SJ, Pasta DJ, Konstan MW. Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint. J Cyst Fibros 2011;10:453–9. 10.1016/j.jcf.2011.07.00321803665
  80. Schechter MS, Regelmann WE, Sawicki GS, Rasouliyan L, VanDevanter DR, Rosenfeld M, et al. Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site. Pediatr Pulmonol 2015;50:431–40. 10.1002/ppul.2314725530325
  81. Morgan WJ, Wagener JS, Pasta DJ, Millar SJ, VanDevanter DR, Konstan MW, Scientific Advisory Group, Investigators, and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Relationship of antibiotic treatment to recovery after acute FEV1 decline in children with cystic fibrosis. Ann Am Thorac Soc 2017;14:937–42. 10.1513/AnnalsATS.201608-615OC28324670
  82. Hoo ZH, Bramley NR, Curley R, Edenborough FP, Walters SJ, Campbell MJ, Wildman MJ. Intravenous antibiotic use and exacerbation events in an adult cystic fibrosis centre: a prospective observational study. Respir Med 2019;154:109–15. 10.1016/j.rmed.2019.06.01731234038
  83. Lechtzin N, Mayer-Hamblett N, West NE, Allgood S, Wilhelm E, Khan U, et al. Home monitoring of patients with cystic fibrosis to identify and treat acute pulmonary exacerbations. eICE Study results. Am J Respir Crit Care Med 2017;196:1144–51. 10.1164/rccm.201610-2172OC28608719
  84. Hoo ZH, Curley R, Campbell MJ, Walters SJ, Hind D, Wildman MJ. Accurate reporting of adherence to inhaled therapies in adults with cystic fibrosis: methods to calculate ‘normative adherence’. Patient Prefer Adherence 2016;10:887–900. 10.2147/PPA.S10553027284242
  85. Lally P, van Jaarsveld CHM, Potts HWW, Wardle J. How are habits formed: modelling habit formation in the real world. Eur J Soc Psyc 2010;40:998–1009. 10.1002/ejsp.674
  86. Tudur Smith C, Hopkins C, Sydes MR, Woolfall K, Clarke M, Murray G, et al. How should individual participant data (IPD) from publicly funded clinical trials be shared? BMC Med 2015;13:298. 10.1186/s12916-015-0532-z26675031
  87. Martin RC. Agile Software Development Principles, Patterns, and Practices. Harlow: Pearson Education Inc.; 2003.
  88. Beck K, Beedle M, van Bennekum A, Cockburn A, Cunningham W, Fowler M, et al. Manifesto for Agile Software Development. Corryton, TN: Agile Alliance; 2001.
  89. Rubin KS. Essential Scrum: A Practical Guide to the Most Popular Agile Process. London: Addison-Wesley Professional; 2012.
  90. Schwaber K. Agile Project Management with Scrum. Redmond, WA: Microsoft Press; 2004. 10.1007/11499053_47
  91. Clegg D, Barker R. Case Method Fast-Track: A RAD Approach. Boston, MA: Addison-Wesley Longman Publishing Co. Inc.; 1994.
  92. Bittner K, Spence I. Use Case Modeling. Boston, MA: Addison-Wesley Longman Publishing Co. Inc.; 2002.
  93. International Organisation for Standardization. ISO/IEC 27000 Family – Information Security Management Systems. Ely: IT Governance Ltd; 2013.
  94. Bandura A. Social cognitive theory of self-regulation. Organ Behav Hum Decis Process 1991;50:248–87. 10.1016/0749-5978(91)90022-L
  95. Carver CS, Scheier MF. Control theory: a useful conceptual framework for personality–social, clinical, and health psychology. Psych Bulletin 1982;92:111. 10.1037/0033-2909.92.1.111
  96. Gardner B. A review and analysis of the use of ‘habit’ in understanding, predicting and influencing health-related behaviour. Health Psych Rev 2015;9:277–95. 10.1080/17437199.2013.876238
  97. Horne R, Weinman J. Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 1999;47:555–67. 10.1016/S0022-3999(99)00057-410661603
  98. Wood W, Neal DT. The habitual consumer. J Consumer Psych 2009;19:579–92. 10.1016/j.jcps.2009.08.003
  99. Lally P, Wardle J, Gardner B. Experiences of habit formation: a qualitative study. Psych Health Med 2011;16:484–9. 10.1080/13548506.2011.555774
  100. Rothman AJ, Sheeran P, Wood W. Reflective and automatic processes in the initiation and maintenance of dietary change. Ann Behaviour Med 2009;38:4–17. 10.1007/s12160-009-9118-3
  101. Michie S, Richardson M, Johnston M, Abraham C, Francis J, Hardeman W, et al. The behaviour change technique taxonomy (v1) of 93 hierarchically clustered techniques: building an international consensus for the reporting of behaviour change interventions. Ann Behav Med 2013;46:81–95. 10.1007/s12160-013-9486-623512568
  102. Craig P, Di Ruggiero E, Frohlich KL, Mykhalovskiy E and White M, on behalf of the Canadian Institutes of Health Research (CIHR)–National Institute for Health Research (NIHR) Context Guidance Authors Group. Taking Account of Context in Population Health Intervention Research: Guidance for Producers, Users and Funders of Research. Southampton: NIHR Evaluation, Trials and Studies Coordinating Centre; 2018. 10.3310/CIHR-NIHR-01
  103. Booth A, Noyes J, Flemming K, Moore G, Tunçalp Ö, Shakibazadeh E. Formulating questions to explore complex interventions within qualitative evidence synthesis. BMJ Glob Heal 2019;4(Suppl. 1):e001107. 10.1136/bmjgh-2018-001107
  104. Pfadenhauer LM, Gerhardus A, Mozygemba K, Lysdahl KB, Booth A, Hofmann B, et al. Making sense of complexity in context and implementation: the Context and Implementation of Complex Interventions (CICI) framework. Implement Sci 2017;12:21. 10.1186/s13012-017-0552-528202031
  105. Yin RK. Case Study Research: Design and Methods. Thousand Oaks, CA: SAGE Publications; 2003.
  106. Curtis L, Burns A. Unit Costs of Health and Social Care 2018. Canterbury: PSSRU, University of Kent; 2018.
  107. Drummond M, Sculpher M, Claxton K, Stoddart G. Methods for the Economic Evaluation of Health Care Programmes. 4th edn. Oxford: Oxford University Press; 2015.
  108. Weinstein MC, O’Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, Luce BR, ISPOR Task Force on Good Research Practices – Modeling Studies. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices – Modeling Studies. Value Health 2003;6:9–17. 10.1046/j.1524-4733.2003.00234.x12535234
  109. Bradley J, Blume S, Stafford M. Quality of Life and Health Utility in Patients with Cystic Fibrosis. European Respiratory Society Annual Congress 2010, September 2010, Barcelona, Spain.
← DiscussionAcknowledgements →

Attribution. Martin J Wildman; Alicia O’Cathain; Daniel Hind; Chin Maguire; Madelynne A Arden; Marlene Hutchings et al. (2021). An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. NIHR Journals Library. Copyright © 2021 Wildman et al. This work was produced by Wildman et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/. For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited. Licensed under CC BY 4.0. NCBI Bookshelf NBK574648. CC BY 4.0. Original source ↗. Text reproduced from the Bookshelf XML without changing wording; figures, images and supplements are not reproduced.

In this chapter Contents

  • References

Source

OpenStax source file ↗

Source record ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Rights and removal requests · Legal · Support